Page 5 | Certara

Press Release

Certara Reports Second Quarter 2025 Financial Results

RADNOR, PA— August 6, 2025-- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development,…

CertaraAugust 6, 2025

Blog

Replacing Traditional TQT Studies with Model-Based Concentration-QTc (C-QTc) Analysis for Cardiovascular Safety in Drug Development

Learn how our experts use concentration-QTc (C-QTc) analysis to replace costly TQT studies, streamline QT…

CertaraAugust 6, 2025

Press Coverage

Modeling Approaches for Determination of Pharmacokinetics/Pharmacodynamics

Explore insights from Certara experts on how PK/PD modeling streamlines biologic drug development.

CertaraAugust 5, 2025

Webinar

De-risking DDI Management during Clinical Trials: Introducing DIDB’s Concomitant Meds Navigator

CertaraAugust 5, 2025

Blog

Breaking New Ground: EMA Qualification of the Simcyp® Simulator Ushers in a New Era for PBPK Modeling

The Simcyp Simulator receives EMA qualification—the first and only PBPK platform formally qualified for any…

CertaraAugust 5, 2025

Webinar

Mechanistic Models at the Regulatory Frontier: Insights from EMA’s Qualification of the Simcyp® Simulator

CertaraAugust 4, 2025

Press Release

Certara Simcyp® Simulator Becomes First and Only Software Platform to Receive EMA Qualification Opinion for PBPK Modeling

Certara announces that EMA has formally qualified the Simcyp® Simulator for use in regulatory submissions…

CertaraAugust 4, 2025

Webinar

Understanding Antibody-Drug Conjugates (ADCs) Pharmacokinetics From NCA to Population PK Approaches

CertaraAugust 1, 2025

Blog

Machine Learning (ML) in healthcare

Learn about 3 distinct examples of machine learning (ML) in healthcare that utilize different techniques…

CertaraAugust 1, 2025

Press Release

Certara Appoints Dr. Chris Bouton as Chief Technology Officer to Advance AI in-silico Drug Discovery and Development Platform

Strengthening technology innovation and leadership of the Certara AI/ML-enabled biosimulation platform used to speed time…

CertaraJuly 31, 2025

Certara Reports Second Quarter 2025 Financial Results

Replacing Traditional TQT Studies with Model-Based Concentration-QTc (C-QTc) Analysis for Cardiovascular Safety in Drug Development

Modeling Approaches for Determination of Pharmacokinetics/Pharmacodynamics

De-risking DDI Management during Clinical Trials: Introducing DIDB’s Concomitant Meds Navigator

Breaking New Ground: EMA Qualification of the Simcyp® Simulator Ushers in a New Era for PBPK Modeling

Mechanistic Models at the Regulatory Frontier: Insights from EMA’s Qualification of the Simcyp® Simulator

Certara Simcyp® Simulator Becomes First and Only Software Platform to Receive EMA Qualification Opinion for PBPK Modeling

Understanding Antibody-Drug Conjugates (ADCs) Pharmacokinetics From NCA to Population PK Approaches

Machine Learning (ML) in healthcare

Certara Appoints Dr. Chris Bouton as Chief Technology Officer to Advance AI in-silico Drug Discovery and Development Platform

Newsletter sign up

Quick links

Solutions

Contact